This is supported by Anthony et al. [24], who reported higher complication rates in insulin-treated GDM, and Gupta et al. [25], who suggested that insulin therapy may be a marker of disease severity rather than simply a treatment modality. The gene discussed is INS; the disease is gestational diabetes.